ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: 402 • 2013 ACR/ARHP Annual Meeting

    Can Modulators Of Inflammation Serve As Biomarkers For Subclinical Atherosclerosis In Rheumatoid Arthritis?

    Kimberly P. Liang1, Douglas P. Landsittel2, Suresh R. Mulukutla3, Steven E. Reis4, Marc C. Levesque5, Donald M. Jones6, Rachel Gartland7, Ali Shoushtari8, Flordeliza S. Villanueva3, Hunter C. Champion8 and Larry W. Moreland5, 1Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, 3Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, 4Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD) and premature atherosclerosis. Mechanisms of atherosclerosis include (1) Endothelial dysfunction/activation mediated…
  • Abstract Number: 265 • 2013 ACR/ARHP Annual Meeting

    All-Cause Mortality and Incident Cardiovascular Disease In Knee Osteoarthritis: The Framingham Study

    Devyani Misra1, David T. Felson2, Ida K. Haugen3, Martin Englund4 and Tuhina Neogi1, 1Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden

    Background/Purpose: Studies examining the relation of osteoarthritis (OA) to mortality or cardiovascular disease (CVD) have reported conflicting results, raising the question of whether OA itself…
  • Abstract Number: 2448 • 2013 ACR/ARHP Annual Meeting

    Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis

    Lianne S. Gensler1, Michael M. Ward2, MinJae Lee3, Mohammad Rahbar4, Matthew A. Brown5, John D. Reveille6 and Michael H. Weisman7, 1Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 2Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, 3Medicine, University of Texas Health Science Center at Houston, Houston, TX, 4The University of Texas Health Science Center at Houston, Houston, TX, 5Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 6Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 7Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA

    Background/Purpose: Cardiovascular disease is an important comorbidity in inflammatory arthritis.  There is evidence that AS patients have a significant burden of cardiovascular comorbidity.  This appears…
  • Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting

    Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis

    Paul A. MacMullan1,2, Anne M. Madigan1, Laura J. Durcan3, Karl Egan2, Paola M. Bagaglia1, Dermot Kenny4 and Geraldine M. McCarthy1, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Cardiovascular Biology Laboratory, RCSI, Dublin, Ireland, 3Rheumatology, Mater Misercordiae University Hospital, Dublin 7, Ireland, 4Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland

    Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…
  • Abstract Number: 694 • 2013 ACR/ARHP Annual Meeting

    Peripheral Bone Marrow-Derived Endothelial Progenitor Cells  and N-Terminal Probrain Natriuretic Peptide  in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report

    Jesús Sepúlveda1,2, Olga Vera-Lastra3, Maria Pilar Cruz-Dominguez4, Laura Montiel-Cervantes5, Joaquín Gómez-León6, Luis Robles-Espinoza7, Ramón Lozano-Morales7, Sergio Mendoza-Alvarez1, Rubiraida Molina-Aguilar5, Gabriela Medina8, Jorge Vela-Ojeda9 and Luis J. Jara10, 1Internal Medicine, Instituto Mexicano del Seguro Social, Mexico City, Mexico, 2Unidad de Estudios de Posgrado, Universidad Nacional Autónoma de México, Mexico City, Mexico, 3Internal Medicine, MD, Mexico City, Mexico, 4Division of Research, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, 5Hematology Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, 6Cardiology Department, Instituto Mexicano del Seguro Social, Mexico City, Mexico, 7Central Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, 8CMN La Raza IMSS, Seris/Zachila s/n La Raza, Mexico City, Mexico, 9Instituto Mexicano del Seguro Social, Mexico City, Mexico, 10Research and Education, Hospital de Especialidades Centro Medico La Raza, México City, Mexico

    Background/Purpose: Diastolic dysfunction (DD) in systemic sclerosis (SSc) is a marker of increased risk of death. The N-terminal pro-brain natriuretic peptide (NT-proBNP) is a neurohormone…
  • Abstract Number: 415 • 2013 ACR/ARHP Annual Meeting

    Stability Of Carotid Intima Media Thickness and No Plaque Formation In Inflammatory Arthritis Patients On Biologics Over One Year

    Stephanie O. Keeling1, Asvina Bissonauth2, Jeff Odenbach2, Quazi Ibrahim3 and Michael Sean McMurtry4, 1Division of Rheumatology, Department of Medicine, University of Alberta, Canada, Edmonton, AB, Canada, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Medicine, EPICORE, Edmonton, AB, Canada, 4Cardiology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Carotid intima media (cIMT) measurement is a validated surrogate measure of cardiovascular (CV) disease. Our aim was to evaluate baseline and follow-up cIMTs in…
  • Abstract Number: 266 • 2013 ACR/ARHP Annual Meeting

    Cardiovascular Disease In Osteoarthritis: Hip Versus Knee and The Influence Of Multiple Symptomatic Joint Involvement

    Anthony V. Perruccio1, Rita A. Kandel2 and Aileen M. Davis3, 1Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Canada, 2Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 3Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The strength of association between obesity and osteoarthritis (OA) is reported to vary by joint (e.g. stronger association with knee than hip). As well,…
  • Abstract Number: 2357 • 2013 ACR/ARHP Annual Meeting

    Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis

    Alper M. van Sijl1, Maarten Boers2, Alexandre E. Voskuyl1 and Mike T. Nurmohamed1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Glucocorticoids (GC) are among the most effective drugs in rheumatoid arthritis (RA), but concerns over long-term side effects have not been resolved. Recent studies…
  • Abstract Number: 1411 • 2013 ACR/ARHP Annual Meeting

    The Peroxisome Proliferator Activated Receptor-gamma pioglitazone Decreases Cardiovascular Risk and Disease Activity In Patients With Rheumatoid arthritis 

    Wendy Marder1, Shokoufeh Khalatbari2, James D. Myles3, Rita Hench4, Susan Lustig4, Srilakshmi Yalavarthi5, Aishwarya Parameswaran4, Robert Brook2 and Mariana J. Kaplan6, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Medicine, University of Michigan at Ann Arbor, Ann Arbor, MI, 3Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5University of Michigan Rheumatology, Ann Arbor, MI, 6Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD

    Background/Purpose: Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease (CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote…
  • Abstract Number: 680 • 2013 ACR/ARHP Annual Meeting

    Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma

    Cory Perugino1, John Stephens2, Colin O'Rourke3 and Soumya Chatterjee4, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified…
  • Abstract Number: 382 • 2013 ACR/ARHP Annual Meeting

    Effect Of Biologic Disease Modifiers On Cardiovascular Risk Of Patients With Rheumatoid Arthritis – 2 Years Prospective Cohort Study

    Majed M. Khraishi1 and Rana Aslanov2, 1Nexus Clinical Research, St John's, NF, Canada, 2Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada

    Background/Purpose: People with RA have a higher risk for developing cardiovascular diseases than the general population. The pathogenic mechanisms in RA appear to be complex…
  • Abstract Number: 220 • 2013 ACR/ARHP Annual Meeting

    Asymptomatic Myocardial Ischemic Disease In Takayasu’s Arteritis: Detection By Magnetic Resonance Imaging

    Cloé Comarmond1, Philippe Cluzel2, Dan Toledano3, Nathalie Costedoat-Chalumeau4, Richard Isnard5, Fabien Koskas6, Patrice Cacoub Sr.7 and David Saadoun8, 1Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, 2Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, 3Cardiovascular Imaging and Interventional Radiology, Hôpital Pitié-Salpêtrière, Paris, France, 4Internal Medicine, Hopital Cochin, Paris, France, 5Cardiology, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, Paris, France, Paris, France, 6Vascular Surgery, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 7Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, 8DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France

    Background/Purpose: Takayasu's arteritis (TA) may affected myocardium and caused coronary stenosis. The aim of this study was to assess the prevalence and pattern of myocardial…
  • Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting

    Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis

    Martin Soubrier1, Thomas Frayssac2, Bruno Pereira3, Marion Couderc Sr.4, Coline Daron2, Jean Jacques Dubost5, Sandrine Malochet-Guinamand4, Anne Tournadre4 and Sylvain Mathieu4, 1Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-ferrand, France, 3Clinical research department, Clermont-Ferrand, France, 4Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 5Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France

    Background/Purpose:  Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and  traditional risk factors could be involved in…
  • Abstract Number: 1387 • 2013 ACR/ARHP Annual Meeting

    Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function

    Michelle J. Ormseth1, Aihua Bian2, Annette M. Oeser2, Andrew Cunningham2, Ayumi Shintani2, S. Bobo Tanner3 and C. Michael Stein4, 1Rheumatology, Vanderbilt Medical Center, Nashville, TN, 2Vanderbilt Medical Center, Nashville, TN, 3Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, 4School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is associated with insulin resistance and increased cardiovascular (CV) risk. Impaired vascular function, including arterial stiffness and endothelial dysfunction, is associated…
  • Abstract Number: 624 • 2013 ACR/ARHP Annual Meeting

    Extremely High Coronary Artery Calcium Scores Among Patients With Systemic Lupus Erythematosus

    Susan Due Kay1, Anne Voss2, Axel Cosmus Pyndt Diederichsen3 and Mikael Kjær Poulsen4, 1Department of Rheumatology, Odense University hospital, University of Southern Denmark, Odense - 5000, Denmark, 2Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, 3Departmen of Cardiology,, Odense University Hospital, Odens-5000, Denmark, 4Department of Cardiology, Odense University Hospital, Odense - 5000, Denmark

    Background/Purpose: Investigations of major lupus-cohorts have demonstrated cardiovascular disease to have major impact on morbidity and mortality (Am J Epidemiol 1997;145:408-15). The aim of this…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology